BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Elizabeth M. Swisher et al.|EBioMedicine|2020Cited by 38
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J. Gray, Carla Grandori, Payel Chatterjee et al.|npj Precision Oncology|2023Cited by 26
A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.Astrid Margossian, Carla Grandori, Madison Pollastro et al.|Journal of Clinical Oncology|2021Cited by 4
Abstract 534: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilitiesGoldie Y.L. Lui, Carla Grandori, Anne B. Richardson et al.|Cancer Research|2021Cited by 4
Abstract 4716: Functional precision medicine: Uncovering high actionability in rare cancers beyond genomicsRachele Rosati, Carla Grandori, Payel Chatterjee et al.|Cancer Research|2025Cited by 1